JP2017057159A - Degradation inhibitors, anti-aging agents, and skin external preparations - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide degradation inhibitors that can inhibit the degradation of dermal matrix components to inhibit skin aging and the like by containing non-flavonoid components derived from Commelina communis var. hortensis (variants are comprised) flower.SOLUTION: The present invention provides a degradation inhibitor that inhibits the degradation of dermal matrix components, the degradation inhibitor containing non-flavonoid components that are derived from at least either the flower of Commelina communis var. hortensis or the flower of a variant of the Commelina communis var. hortensis.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a decomposition inhibitor, an anti-aging agent, and a skin external preparation. More specifically, the present invention relates to a degradation inhibitor, an anti-aging agent, and a skin external preparation that suppresses skin aging and the like by inhibiting degradation of the matrix component of the dermis.

  The dermis that constitutes the skin is mainly composed of fibroblasts and matrix components. Fibroblasts produce proteins such as collagen and glycosaminoglycans such as hyaluronic acid to form connective tissue and play an important role in the skin. Therefore, when collagen, hyaluronic acid, etc. decrease, the connective tissue disintegrates and the skin ages, causing wrinkles, sagging, loss of texture, reduced elasticity, and the like. Thus, external preparations for skin that can activate the synthesis of collagen and hyaluronic acid by activating fibroblasts have been studied.

  It has been known that many plant extracts have various physiological actions so far. For example, it is known that flavonoids contained in the alcoholic extract can be applied as hyaluronic acid synthesis promoter, anti-aging agent and skin external preparation (Patent Document 1).

JP 2008-94792 A

  However, the technique disclosed in Patent Document 1 merely discloses that the above-described effects can be achieved by containing a flavonoid derived from the giant burdock. In addition, the technique disclosed in Patent Document 1 uses whole plant of sorghum, and an alcohol extract is used.

  Unlike the prior art, the present invention contains a non-flavonoid component derived from the flower of the giant burdock (including variant), thereby suppressing degradation of the matrix component of the dermis and suppressing skin aging, etc. It is an object of the present invention to provide a decomposition inhibitor, an anti-aging agent, and a skin external preparation that can be used.

  The decomposition inhibitor, anti-aging agent, and external preparation for skin of the present invention that solves the above problems mainly include the following constitutions.

  (1) A decomposition inhibitor that suppresses the decomposition of matrix components of the dermis, and contains a non-flavonoid component derived from at least one of the flowers of the burdock flower or a variant of the burdock flower. Agent.

  According to such a configuration, the decomposition inhibitor can suppress the decomposition of the matrix component of the dermis due to the contribution of the non-flavonoid component. As a result, skin aging and the like can be suppressed.

  (2) The degradation inhibitor according to (1), wherein the non-flavonoid component is contained in an extract of a petal among the flowers of the scorpiona or the variant of the scorpiona.

  Oboushibana flower (blue flower) is used as a dye for Yuzen dyeing. In addition, the flowers of varieties of white-spotted beetle (for example, the whitening and white winged Nakamura No. 1 (white flowers)) have no pigment component and therefore have no use as dyes. However, according to such a configuration, the decomposition inhibitor can effectively use the flower of the scabbard, which has no active use other than the above-described dye use, as a decomposition inhibitor capable of suppressing the decomposition of the matrix component of the dermis.

  (3) The degradation inhibitor according to (1) or (2), which suppresses the expression of matrix metalloproteinases (MMPs) that degrade the matrix components.

  According to such a configuration, the degradation inhibitor can suppress the expression of MMPs, which are degradation enzymes that degrade the dermal matrix components. As a result, decomposition of the matrix component of the dermis is more easily suppressed.

  (4) The degradation inhibitor according to any one of (1) to (3), which inhibits the activity of an enzyme elastase that degrades elastin contained in the matrix component.

  According to such a configuration, the degradation inhibitor inhibits the activity of the enzyme elastase that degrades elastin, which is a matrix component of the dermis. Therefore, elastin is difficult to be decomposed. As a result, decomposition of the matrix component of the dermis is more easily suppressed.

  (5) An anti-aging agent that suppresses the degradation of the matrix component of the dermis, and contains a non-flavonoid component derived from at least one of the flowers of the bursa or varieties of the bursa Agent.

  According to such a structure, the anti-aging agent can suppress decomposition | disassembly of the matrix component of a dermis by the contribution of a non-flavonoid component. As a result, aging of the skin can be suppressed.

  (6) A skin external preparation that suppresses the decomposition of the matrix component of the dermis, and contains a non-flavonoid component derived from at least one of the flowers of the burdock flower or a variant of the burdock flower Agent.

  According to such a structure, the skin external preparation can suppress decomposition | disassembly of the matrix component of a dermis by the contribution of a non-flavonoid component. As a result, skin aging and the like can be suppressed.

  According to the present invention, it is possible to provide a decomposition inhibitor, an anti-aging agent, and a skin external preparation that can suppress the decomposition of the matrix component of the dermis and suppress the aging of the skin and the like by the contribution of the non-flavonoid component. .

FIG. 1 shows the results of SDS-PAGE showing the MMP-1 expression inhibitory effect of the degradation inhibitors prepared in Examples 1 to 3 and Comparative Example 1. FIG. 2 shows the results of SDS-PAGE showing the MMP-3 expression inhibitory effect of the degradation inhibitors prepared in Examples 1 to 3 and Comparative Example 1.

  The decomposition inhibitor of one embodiment of the present invention is a decomposition inhibitor that suppresses decomposition of the matrix component of the dermis. Moreover, the decomposition inhibitor contains a non-flavonoid component derived from at least one of the flowers of the syllabary flower or the varieties of the syllabary flower.

  The large-bellied plant (C. communis var. Hortensis) is a plant of the Commelinaceae family. Oboushibana is also called Aoka, and is mainly used as a dye for Yuzen dyeing. In addition, the white-spotted Nakamura Ichigo (white flower), whose expression of blue pigments has been greatly reduced, is known as a large-sized beech. The decomposition inhibitor of the present embodiment contains a non-flavonoid component derived from at least one of the flowers of the burrowed flower and the varieties of burrowed flower. In addition, in this specification, large-sized beetle and its variant are also called simply large-sized beetle.

  In this embodiment, a non-flavonoid component refers to components other than a flavonoid among the components contained in flowers, such as a giant syllabary. Non-flavonoid components are abundant in the petals, especially among flowers. Such a non-flavonoid component is not particularly limited. As an example, the non-flavonoid component is a component contained in a water fraction when an extract is obtained from a flower such as a large-browed bee by the following method. The extract (moisture fraction) of the present embodiment contains 1% by mass or less of a flavonoid component, and is preferably substantially not contained.

  That is, first, the petals after harvesting, such as large-sized beetle (which may be cryopreserved), are extracted with water, an alcohol solvent, or a water / alcohol mixed solvent (an example of an alcohol extraction step). The alcohol solvent is not particularly limited. As an example, the alcohol solvent is a lower alcohol (including those diluted with water). Examples of the lower alcohol include methanol, ethanol, propanol, butanol and the like. The alcohol solvent in the water / alcohol mixed solvent preferably has a concentration range of 50 to 80%. The extraction conditions with an alcohol solvent are not particularly limited. As an example, alcohol extraction can be performed by holding a large-sized beetle or the like in an alcohol solvent and holding at 5 ° C. or lower (in a refrigerator) for about one week.

  Further, the amount of the extraction solvent at the time of extraction is preferably 100 parts by weight or more, more preferably 500 parts by weight or more, with respect to 100 parts by weight of the large beetle. The amount of the extraction solvent is preferably 100,000 parts by weight or less, and more preferably 10,000 parts by weight or less. When the amount of the extraction solvent is less than 100 parts by weight, the extraction efficiency tends to deteriorate. On the other hand, when the amount of the extraction solvent exceeds 100,000 parts by weight, there is a tendency that improvement in extraction efficiency cannot be expected, and it takes time for concentration and purification, and there is a tendency that production efficiency is lowered. The temperature during extraction is not particularly limited. As an example, the temperature is 60 to 80 ° C. Moreover, the immersion time at the time of extraction is not specifically limited. As an example, the immersion time is 60 to 120 minutes. The extraction operation may be performed twice or more.

  The obtained extract stock solution may be used as it is. Preferably, the extract stock solution is subjected to purification operations such as removal of impurities, deodorization, decolorization, and concentration. Examples of the purification operation include filtration, gel filtration, centrifugation, chromatography, distillation, distribution method and the like.

  In the decomposition inhibitor of this embodiment, components are preferably separated by chromatography, for example. As an adsorption carrier for column chromatography, Diaion HP-20 (manufactured by Mitsubishi Chemical Corporation) that is washed with methanol and then replaced with water can be used. Diaion HP-20 is added to the extract stock solution, and the solvent is distilled off. Thereby, the extract component in the extract stock solution is adsorbed on the adsorption carrier. This is transferred into a chromatographic tube, and water, 50% ethanol, and 100% ethanol are added in this order as an elution solvent to obtain respective elution components (elution step).

  According to the above elution process, the flavonoid component is mainly contained in fractions other than the water fraction, and is not substantially contained in the water fraction. That is, the components contained in the water fraction are mainly non-flavonoid components.

  The water fraction may then be evaporated and then lyophilized (drying step). The solvent can be distilled off and lyophilized by a conventional method.

  The non-flavonoid component obtained by the above operation effectively suppresses the decomposition of the matrix component of the dermis. Specifically, the degradation inhibitor containing a non-flavonoid component can inhibit the expression of MMPs, which are degrading enzymes that degrade the matrix component of the dermis.

  MMPs are a group of degrading enzymes that degrade the dermal matrix. MMPs are activated by exposure to stress such as ultraviolet rays, oxidation, and inflammation, and can cause skin elasticity reduction and wrinkle increase. MMPs include MMP-1 and MMP-3, which are typical enzymes that degrade collagen. The degradation inhibitor of this embodiment can suppress the expression of these MMPs (particularly MMP-1 and MMP-3). Therefore, decomposition of the matrix component of the dermis can be suppressed, and skin aging or the like can be suppressed.

  Moreover, the degradation inhibitor containing a non-flavonoid component can inhibit the activity of the enzyme elastase that degrades elastin, which is a matrix component of the dermis.

  Elastin is called an elastic fiber and exhibits excellent elasticity. For this reason, it is often contained in organs that require elasticity, such as ligaments, blood vessels, lungs, and the dermis of the skin. In the dermis, elastin plays an important role in bundling collagen and producing elasticity. The degradation inhibitor of this embodiment can inhibit the activity of an enzyme elastase that degrades such elastin (particularly, the enzyme elastase derived from fibroblasts). Therefore, decomposition of the matrix component of the dermis can be suppressed, and aging of the skin (formation of wrinkles and sagging) can be suppressed.

  The content of the non-flavonoid component contained in the decomposition inhibitor is not particularly limited. The non-flavonoid component is preferably 0.00001% by weight or more, and more preferably 0.0001% by weight or more in the decomposition inhibitor. Further, the non-flavonoid component is preferably 10% by weight or less, and more preferably 1% by weight or less in the decomposition inhibitor. When the content is less than 0.00001% by weight, the effect of suppressing the decomposition of the matrix component of the dermis tends not to be sufficiently obtained. On the other hand, when the content exceeds 10% by weight, there is a tendency that further effects cannot be expected.

  As described above, the decomposition inhibitor of the present embodiment contains a non-flavonoid component derived from a flower such as the giant burdock as described above, and suppresses the decomposition of the matrix component of the dermis. Therefore, the decomposition inhibitor can be used as, for example, an anti-aging agent, a skin external preparation, and the like. The form of the decomposition inhibitor is not particularly limited. The decomposition inhibitor can be in various forms such as a lotion, emulsion, gel, sol, cream, ointment, powder, spray and the like. When used as an anti-aging agent, the decomposition inhibitor can be used for applications such as wrinkle prevention and improvement and skin aging prevention. In addition, when used as a skin external preparation, especially in the form of a cosmetic, the decomposition inhibitor is a cosmetic for skin such as lotion, milk, cream, cosmetic liquid, pack, face wash, makeup base lotion, makeup. Makeup cosmetics such as base cream, foundation, liquid foundation, lipstick, body cosmetics such as hand cream, leg cream, body lotion, body soap and soap, and cosmetics for hair such as shampoo, rinse and hair nourishing agent. Can do.

  In addition, when the decomposition inhibitor of this embodiment is used in the above-described form, known additives and the like may be appropriately blended. For example, decomposition inhibitors include oils and fats, waxes, hydrocarbons, fatty acids, lower alcohols, higher alcohols, polyhydric alcohols, esters, esters, Even if molecules, surfactants, moisturizers, anti-inflammatory agents, ultraviolet absorbers, antiseptics, antifungal agents, fragrances, pigments, excipients, antioxidants, cosmetic ingredients, cosmetic stabilizers, etc. Good. Further, the degradation inhibitor of the present embodiment may be blended with other cell activators, anti-aging agents, collagen synthesis promoters, hyaluronic acid synthesis promoters, and the like.

  Hereinafter, the present invention will be described more specifically with reference to examples. The present invention is not limited to these examples.

<Preparation of Streptomyces extract (non-flavonoid component)>
After harvesting, 1 kg of the petals of each of the arched beetle (blue flowers) and the varieties (white flowers) that were cryopreserved were immersed in 2 L of 50% ethanol, kept in a refrigerator at 4 ° C. for 1 week, filtered, A 50% ethanol extract stock solution was obtained. For each extract stock solution, Diaion HP-20 (manufactured by Mitsubishi Chemical Corporation) in which the adsorption carrier was washed with methanol and replaced with water was added, and the solvent was distilled off and adsorbed on the adsorption carrier. The adsorption carrier was transferred into a chromatographic tube, and water, 50% ethanol, and 100% ethanol were added in this order as an elution solvent to obtain respective elution components. Of these, only the water fraction was evaporated and then lyophilized. As a dry powder, 17.5 g each of the extract of non-flavonoid (non-flavonoid component) was obtained.

Example 1
The obtained extract of scorpiona (blue flower) was diluted with purified water so that the concentration of the non-flavonoid component was 250 (μg / mL), and the degradation inhibitor of Example 1 was prepared.

(Example 2)
The decomposition inhibitor of Example 2 was prepared in the same manner as in Example 1 except that the dilution concentration was changed so that the concentration of the non-flavonoid component was 500 (μg / mL).

(Example 3)
The decomposition inhibitor of Example 3 was prepared in the same manner as in Example 1 except that the dilution concentration was changed so that the concentration of the non-flavonoid component was 1000 (μg / mL).

Example 4
The obtained extract of the succulent variant (white flowers) was diluted with purified water so that the concentration of the non-flavonoid component was 250 (μg / mL), and the degradation inhibitor of Example 4 was prepared.

(Example 5)
The decomposition inhibitor of Example 5 was prepared in the same manner as in Example 1 except that the dilution concentration was changed so that the concentration of the non-flavonoid component was 500 (μg / mL).

(Example 6)
The decomposition inhibitor of Example 6 was prepared in the same manner as in Example 1 except that the dilution concentration was changed so that the concentration of the non-flavonoid component was 1000 (μg / mL).

  About the degradation inhibitor prepared in Examples 1-6, the MMP-1 activity inhibitory effect and the fibroblast origin elastase activity inhibitory effect were confirmed according to the following method. The results are shown in Table 1.

<Confirmation of MMP-1 activity inhibitory effect>
MMP-1 enzyme (Human recombinant MMP-1 in E. coli (recombinant) (manufactured by Sigma)) and substrate (MOCAc-Pro-Leu-Gly-Leu-A2pr (Dnp) -Ala-Arg-NH ₂ ( Peptide Laboratories Co., Ltd. was prepared, and these were appropriately diluted with TNCB buffer (50 mM Tris, 10 mM CaCl ₂ , 150 mM NaCl, 0.05% Briji-35, pH 7.5) First, a sample solution of 50 μL Next, 100 μL of the enzyme solution was added and incubated at 37 ° C. for 10 minutes in the dark, and then 50 μL of the substrate solution was added and further incubated for 60 minutes in the dark at 37 ° C. After completion, immediately with a fluorimeter. Measure fluorescence intensity at excitation wavelength 320nm and fluorescence wavelength 405nm. . Based on the fluorescence intensity obtained, the inhibition rate (%) = 100 - [(A-B) / (C-D)] × 100
A: Fluorescence intensity at 405 nm of test solution B: Fluorescence intensity at 405 nm of test solution blank C: Fluorescence intensity at 405 nm of control solution D: MMP-1 activity inhibitory effect (inhibition) according to the formula of fluorescence intensity at 405 nm of control solution blank Rate (%)). Note that a TNCB buffer not containing a non-flavonoid component was used as a decomposition inhibitor for the blank (Comparative Example 1).

<Confirmation of fibroblast-derived elastase activity inhibitory effect>
Normal human dermal fibroblasts (NHDF) (manufactured by Kurabo Industries, Ltd.) were seeded at a density of 6.3 × 10 ⁴ cells / cm ^{2 in} a 60 mm dish and cultured overnight at 37 ° C. with 5% CO ₂ . Thereafter, the plate was washed twice with PBS (−), 325 μL of 0.5% Triton X-100 was added and allowed to stand at room temperature for 30 minutes to lyse the cells. The cell lysate was collected and sonicated twice for 15 seconds to obtain a crude enzyme extract. As the medium, Dulbecco's modified eagle (DMEM) (manufactured by Nissui Pharmaceutical Co., Ltd.) medium containing 5% bovine serum (FBS) was used. N-succinyl-Ala-Ala-Ala-p-nitroanilide dissolved in dimethyl sulfoxide (DMSO) to a concentration of 0.1 M and diluted to 5 mM with 0.1 M Tris-HCl (pH 8.0) A substrate solution was obtained. Using a 96-well plate, 50 μL of the crude enzyme solution was added to 50 μL of the sample solution, and then 100 μL of the substrate solution was added, followed by incubation at 37 ° C. for 2 hours. Immediately after completion of the reaction, absorbance at 405 nm was measured with a spectrophotometer. The elastase activity inhibition rate was calculated by the following formula. In addition, it prepared by the same method except having added 50 microliters of 0.5% Triton X-100 instead of the enzyme solution as a decomposition inhibitor of a blank (comparative example 2), and confirmed the elastase activity inhibitory effect.
Inhibition rate (%) = 100 − [(A−B) / (C−D)] × 100
A: Absorbance at 405 nm of test solution B: Absorbance at 405 nm of test solution blank C: Absorbance at 405 nm of control solution D: Absorbance at 405 nm of control solution blank

  As shown in Table 1, all of the degradation inhibitors of Examples 1 to 6 containing non-flavonoid components derived from flowers such as giant burrows had an MMP-1 activity inhibitory effect and an elastase activity inhibitory effect. . As a result, it was found that the degradation inhibitor of the present invention can suppress the degradation of the matrix component of the dermis and suppress the aging of the skin due to the contribution of the non-flavonoid component.

  About the decomposition inhibitor prepared in Examples 1-3 and the comparative example 1, the MMPs protein expression inhibitory effect was confirmed according to the following method. The results are shown in FIGS.

<MMPs protein expression inhibitory effect>
(culture)
NHDF was seeded on a 24-well microplate at a density of 1.2 × 10 ⁶ cells / cm ² , cultured at 5% CO ₂ at 37 ° C. for 24 hours, and then the sample-added medium was changed. When changing the medium, the medium was washed twice with PBS (−), replaced with an appropriate amount of FBS or bovine serum albumin (BSA), and further cultured for 24-48 hours. MMPs production was induced by adding IL-1α (sigma: I2778). As the medium, DMEM medium containing 1% FBS was used.
(Protein extraction method)
The culture supernatant was recovered from each well, and an equal volume of 2 × sample buffer (125 mM Tris-HCl (pH 8.8), 20% glycerol, 4% SDS, 0.01% bromophenol blue, 200 mM DTT (dithiothrei Toll)) and boiled at 98 ° C. for 15 minutes. In addition, protein quantification of cells was performed for standardization. The medium in the well was removed, washed twice with PBS (−), and after removal, 200 μL of 2% SDS was added, recovered with a pipette, sonicated twice for 15 seconds, and BCA Protein Assay Kit (Thermo Scientific) ).
(SDS-PAGE)
10% acrylamide gel (separation gel: 10% polyacrylamide (manufactured by BioRad), 0.375 M Tris-HCl (pH 8.8), 0.1% SDS (sodium laureth sulfate), 0.033% APS ( Ammonium persulfate) and 0.05% TEMED (N, N, N ′, N′-tetramethylethane-1,2-diamine), concentrated gel: 4.75% polyacrylamide, 0.125 M Tris HCl ( pH 6.8), 0.1% SDS, 0.033% APS and 0.05% TEMED). A running gel and a stacking gel were overlaid on two glass plates to form a 10% acrylamide gel. The electrophoresis was performed using SDS-PAGE buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) at a constant current of 20 mA for 90 minutes.
(Blotting)
Using a tank type blotting apparatus, transfer was performed at a constant current of 200 mA for 2 hours. Transfer was performed on a PVDF membrane (manufactured by GE Healthcare) using a transfer buffer (124 mM Tris, 30 mM Glycine, 0.01% SDS and 20% MeOH).
(Antibody reaction and detection)
As primary antibodies, anti-MMP-1 antibody (abcam: EP1247Y, R & D: AF901) and anti-MMP-3 antibody (abcam: EP1186Y) were used. Anti-rabbit IgG-HRP (GE Healthcare: NA934) and anti-goat IgG-HRP (santa cruz: 2033) were used as secondary antibodies. As an antibody detection reagent, ECL prime (manufactured by GE Healthcare) was used.

  FIG. 1 shows the results of SDS-PAGE showing the MMP-1 expression inhibitory effect of the degradation inhibitors prepared in Examples 1 to 3 and Comparative Example 1. FIG. 2 shows the results of SDS-PAGE showing the MMP-3 expression inhibitory effect of the degradation inhibitors prepared in Examples 1 to 3 and Comparative Example 1.

  The band of MMP-1 protein appeared in the vicinity of 50 kDa in FIG. Since the degradation inhibitor of Comparative Example 1 had no effect of suppressing the expression of MMP-1, when irradiated with UV (+ UV), the production of MMP-1 was enhanced, and a dark band appeared in the vicinity of 50 kDa. On the other hand, the degradation inhibitors of Examples 1 to 3 decreased the expression of enhanced MMP-1. As a result, the band near 50 kDa became thin. Thereby, it was shown that the decomposition inhibitor of Examples 1-3 is excellent in the expression inhibitory effect with respect to MMP-1 protein.

  Similarly, the band of MMP-3 protein appeared in the vicinity of 50 kDa in FIG. Since the degradation inhibitor of Comparative Example 1 had no effect of suppressing the expression of MMP-3, irradiation with UV (+ UV) increased MMP-3 production, and a dark band appeared in the vicinity of 50 kDa. On the other hand, in the degradation inhibitors of Examples 1 to 3, enhanced MMP-3 expression was decreased. As a result, the band near 50 kDa became thin. Thereby, it was shown that the decomposition inhibitor of Examples 1-3 is excellent in the expression inhibitory effect with respect to MMP-3 protein.

<Prescription example>
Next, the formulation example using the decomposition inhibitor of this invention is illustrated. Any of these degradation inhibitors can be prepared by conventional methods. In addition, it was confirmed in advance that the degradation inhibitors of these prescription examples all suppressed degradation of the matrix component of the dermis and could suppress skin aging and the like.

(Formulation Example 1: Cream)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 2.0
Sodium hyaluronate 0.01
Glyceryl monostearate 3.0
Polyoxyethylene (20) sorbitan monostearate 3.0
Cetanol 2.0
Squalane 3.0
Glyceryl 2-ethylhexanoate 10.0
Glycerin 7.0
Ethylparaben 0.1
Purified water balance Total 100.0

(Formulation Example 2: Cream)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 1.0
Stearic acid 10.0
Cetanol 2.0
Lanolin 1.0
Isopropyl myristate 3.0
Polyethylene glycol monostearate 1.5
Triethanolamine 0.8
Sorbitol (70%) 4.0
Methylparaben 0.1
Fragrance 0.01
Purified water balance Total 100.0

(Prescription Example 3: Liquid Foundation)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 0.1
Hyaluronic acid 0.01
Glyceryl monostearate 2.0
Polyoxyethylene (4) sodium lauryl ether phosphate 0.5
Stearic acid 5.0
Behenyl alcohol 1.0
Lanolin 2.0
Squalane 5.0
Glyceryl 2-ethylhexanoate 4.0
Pigment 10.0
Propylene glycol 7.0
Triethanolamine 1.0
Ethylparaben 0.1
Purified water balance Total 100.0

(Prescription Example 4: Liquid Foundation)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 0.1
Lanolin 2.0
Liquid paraffin 5.0
Stearic acid 2.0
Cetanol 1.0
Glycerin 2.0
Squalane 5.0
Glyceryl 2-ethylhexanoate 4.0
Pigment 10.0
Propylene glycol 7.0
Triethanolamine 1.0
Ethylparaben 0.1
Fragrance 0.01
Purified water balance Total 100.0

(Formulation Example 5: Emulsion)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 0.5
Hyaluronic acid 0.01
Stearic acid 2.0
Ethanol 0.5
Liquid paraffin 10.0
Lanolin Fatty Acid Isopropyl 3.0
Lanolin 4.0
Squalane 5.0
Sorbitan sesquiisostearate 1.0
Propylene glycol 5.0
Triethanolamine 0.6
Ethylparaben 0.1
Fragrance 0.01
Purified water balance Total 100.0

(Formulation Example 6: Latex)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 0.5
Stearic acid 3.5
Ethanol 0.5
Liquid paraffin 3.0
Lanolin 0.5
Squalane 2.0
Propylene glycol 3.0
Triethanolamine 0.8
Ethylparaben 0.1
Carboxyvinyl polymer 1% liquid (alkali neutralization) 8.0
Fragrance 0.01
Purified water balance Total 100.0

(Formulation example 7: lotion)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 0.05
Sodium hyaluronate 0.01
Polyoxyethylene (20) sorbitan monolaurate 1.0
1,3-butylene glycol 3.0
Sorbitol (70%) 2.0
Sodium pyrrolidonecarboxylate solution 3.0
Ethanol 15.0
Ascorbic acid 0.1
Methylparaben 0.1
Fragrance 0.01
Purified water balance Total 100.0

(Formulation example 8: lotion)
Blue or white flower petal extract (freeze-dried non-flavonoid component) 0.05
Polyoxyethylene (20) sorbitan monolaurate 1.0
1,3-butylene glycol 5.0
Sorbitol (70%) 2.0
Sodium pyrrolidonecarboxylate solution 3.0
Ethanol 15.0
Ascorbic acid 0.1
Methylparaben 0.1
Dye 0.01
Fragrance 0.01
Purified water balance Total 100.0

Claims (6)

It is a decomposition inhibitor that suppresses the decomposition of the dermal matrix components
A decomposition inhibitor containing a non-flavonoid component derived from at least one of the flowers of the giant syllabary or the variant of the syllabary.   The degradation inhibitor according to claim 1, wherein the non-flavonoid component is contained in a petal extract of the flowers of the sorghum or a variety of sorghum.   The degradation inhibitor of Claim 1 or 2 which suppresses the expression of the matrix metalloprotease which decomposes | disassembles the said matrix component.   The degradation inhibitor of any one of Claims 1-3 which inhibits the activity of the enzyme elastase which decomposes | disassembles the elastin contained in the said matrix component. It is an anti-aging agent that suppresses the decomposition of matrix components of the dermis,
An anti-aging agent containing a non-flavonoid component derived from at least one of the flowers of the scorpiona or the varieties of the scorpiona. It is a skin external preparation that suppresses the decomposition of the matrix component of the dermis,
A topical skin preparation containing a non-flavonoid component derived from at least one of the flowers of the scorpiona or the variant of the scorpiona.